<DOC>
	<DOCNO>NCT02374047</DOCNO>
	<brief_summary>This 2-part , Phase 1 , placebo-controlled , double-blind , randomize , single multiple ascend dose study . CAT-2054 administer either uncoated capsule ( CAT-2054 ) coat capsule ( CAT-2054-C ) . In Part A , CAT-2054 placebo administer single dose fast state 4 dose level ; 3 dose level , subject return second dose study drug high-fat meal . Additionally , 1 dose level , CAT-2054-C placebo administer single dose fast state , subject return second dose study drug high-fat meal . In Part B , CAT-2054 administer multiple ascending dose 4 dose level 14 consecutive day . In select cohort , CAT-2054 , CAT-2054-C CAT-2054 atorvastatin dose assess safety anticipation future clinical trial .</brief_summary>
	<brief_title>A 2-Part , Phase 1 , Single Multiple Ascending Dose Study Assess Safety , Pharmacokinetics , Pharmacodynamics CAT-2054 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Provision write informed consent studyspecific procedure Good health determine medical history , physical examination , vital sign measurement , ECG , clinical laboratory measurement Satisfies one following : 1 . Females childbearing potential : nonpregnant nonlactating surgically sterile postmenopausal 2 year less folliclestimulating hormone assessment great equal 40 IU/L 2 . Males : surgically sterile , abstinent , subject partner utilize acceptable contraceptive method 3 month last study dose For Part B , measure Screening : Fasting LDLC ≥100 mg/dL ; ( Cohort B6 ) fast LDLC ≥130 mg/dL Body mass index ( BMI ) 18 30 kg/m² , inclusive , Part A 18 40 kg/m² , inclusive , Part B , body weight &gt; 50 kg Screening Use prescription drug nonprescription drug include herbal , dietary supplement ( include multivitamin product contain niacin omega3 fatty acid Recommended Daily Allowance ) within 2 week dose . Additionally Part B , use lipidregulating prescription drug , nonprescription drug , herbal , dietary supplement within 6 week dose Clinically significant disease require physician 's care and/or would interfere study evaluation Clinically significant electrocardiogram ( ECG ) abnormalities laboratory result assess investigator , QTcF &gt; 450 Use investigational drug participation investigational study within 30 day prior screen 5 halflives study agent , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>